No black box warning on record for Kebilidi

As of the latest FDA labeling reviewed, Kebilidi (ELADOCAGENE EXUPARVOVEC-TNEQ) does not carry a black box warning. Standard warnings and precautions still apply — see the full Kebilidi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Procedural complications: Monitor patients for procedural complications for neurosurgery, including events of respiratory and cardiac arrest after administration of KEBILIDI. ( 5.1 ) Dyskinesia: Monitor patients for dyskinesia after treatment with KEBILIDI. The use of dopamine antagonists can be used to control dyskinesia symptoms. ( 5.2 ) 5.1 Procedural Complications Pr

No black box warning on record for Kebilidi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Procedural complications: Monitor patients for procedural complications for neurosurgery, including events of respiratory and cardiac arrest after administration of KEBILIDI. ( 5.1 ) Dyskinesia: Monitor patients for dyskinesia after treatment with KEBILIDI. The use of dopamine antagonists can be used to control dyskinesia symptoms. ( 5.2 ) 5.1 Procedural Complications Pr

Kebilidi Black Box Warning

No black box warning on record for Kebilidi

Other warnings & precautions

Kebilidi Black Box Warning

No black box warning on record for Kebilidi

Other warnings & precautions